Prof Salvatore Siena talks to ecancertv at the ESMO 14th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona.

In the interview he discusses the concept of personalised medicine, one of the major themes of this year’s WCGC. He notes that advances have been made in understanding the possible mechanisms of resistance to molecularly-targeted therapies for colorectal cancer (CRC).

Prof Siena comments on some of the hot topics in CRC, such as the influence of Kras mutations on response to treatments such as cetuximab. He also notes that Kras mutations might be detectable in the peripheral blood.

Prof Siena also gives his personal views on next steps in the field of gastrointestinal (GI) oncology in relation to CRC. 

This programme was supported by BAYER.